Background: Clinical responses to ipilimumab are variable in terms of onset, magnitude and duration. Upfront identification of patients who are more likely or unlikely to benefit from treatment is a major need.
introduction Ipilimumab (Yervoy, Bristol-Myers Squibb), a fully human monoclonal antibody that blocks the immune checkpoint cytotoxic T-lymphocyte antigen 4, improved overall survival (OS) of metastatic melanoma patients in two randomized phase III studies, but it is effective only in a proportion of patients and it is not devoid of side-effects [1, 2] .
A number of blood-derived parameters have been associated with survival of ipilimumab-treated patients [3] [4] [5] [6] [7] [8] , including markers of systemic inflammation such as baseline absolute neutrophil count (ANC) and the neutrophil-to-lymphocyte ratio (NLR) [9] [10] [11] [12] . The derived NLR (dNLR), composed of white cell counts (WBC) and ANC, has been proposed as an alternative to NLR for those studies in which only WBC and ANC have been recorded [13] .
Here, we evaluated the associations of baseline ANC and dNLR with the outcome of 720 patients enrolled in an expanded access program (EAP) in Italy for ipilimumab 3 mg/kg. After having shown that each parameter was associated with survival, we reasoned that their combination could provide stronger and more reliable indications, and we propose that a neutrophilbased index may enable stratification of patients into risk groups with different probabilities to benefit from treatment.
materials and methods patients
This study analyzed prospectively collected data from patients who received compassionate use of ipilimumab through the Italian EAP [14] . The treatment was approved by a local independent ethics committee, and all participating patients signed informed consent before enrollment. Patients were eligible for this analysis if they had baseline WBC and ANC recorded in the EAP database.
treatment and assessments
Ipilimumab was administered i.v. at 3 mg/kg every 3 weeks for four infusions. Complete blood cell counts with differential count and serum chemistry were carried out at baseline and before each drug infusion as part of routine oncological practice. WBC and ANC, but not lymphocyte, monocyte, eosinophil and basophil counts, were recorded as part of the study. Lactate dehydrogenase (LDH) levels, together with the upper limit of normal (ULN), were collected in eight centers. Tumor assessment was carried out at baseline, at week 12 and every 12 weeks thereafter, and clinical responses were classified according to immune-related response criteria [15] .
statistical analysis
Patient and disease characteristics were presented using descriptive statistics [relative frequencies ( percentage) for discrete variables, median and range for continuous variables]. Neutrophilia was defined as baseline ANC exceeding 7500 cell/µl [16] . The dNLR was calculated: dNLR = ANC/(WBC−ANC) [13] . The optimal cutoff value for dNLR was assessed by time-dependent receiver operating characteristic (ROC) curve analysis and analysis of the area under the curve (AUC). Associations of ANC and dNLR with patient characteristics were analyzed by χ 2 -and Mann-Whitney U-tests, as appropriate. OS was calculated from first treatment to death (event) or last follow-up (censored). Progression-free survival (PFS) was calculated from first treatment to disease progression or death (event), or last follow-up (censored). OS and PFS curves were estimated with the Kaplan-Meier method. Associations of ANC and dNLR, and their combinations, with OS and PFS were tested with the log-rank test. Multivariate Cox proportional hazard models adjusted for age, gender, Eastern Cooperative Oncology Group performance status (ECOG PS), number of previous therapies, presence of liver and/or brain metastasis and accrual Center were used to assess independent prognostic values of ANC, dNLR, LDH and their combinations, for OS and PFS. Results were presented as hazard ratios (HR) with 95% confidence intervals (95% CIs). IBM SPSS, version n.20 was used for the analysis.
results

patient characteristics
Between June 2010 and January 2012, 855 advanced melanoma patients received ipilimumab 3 mg/kg within the EAP across 55 Italian centers. Among them, 720 (84%) patients had baseline WBC and ANC recorded and were eligible for this analysis (supplementary Figure S1 , available at Annals of Oncology online). As of April 2013, 178 (25%) patients were still alive. One patient was lost to follow-up, being only the date of death available. With a median follow-up of 16.5 months, the median OS and PFS were 7.4 and 3.7 months, respectively. Patient characteristics (supplementary Table S1 , available at Annals of Oncology online) and the outcome of the study population were comparable with those of all patients participating to the Italian EAP [14] .
baseline ANC and survival
Ninety-one patients (13%) presented with baseline neutrophilia. Elevated ANC was associated with male gender (P = 0.002), ECOG PS > 0 (P < 0.0001) and liver metastasis (P = 0.05), but not with other variables (P > 0.05 for all, supplementary Table S1 , available at Annals of Oncology online).
Median OS and PFS were 8.7 (95% CI 7.7-9.8) months and 4.0 (95% CI 3.5-4.5) months, respectively, for patients with normal ANC, compared with 2.3 (95% CI 1.5-3.1) and 1.7 (95% CI 1.0-2.3) months, respectively, for patients with elevated ANC ( Figure 1A and B, P < 0.0001 for both). In multivariate analysis, ECOG PS 1 or 2, the presence of brain and liver metastasis and neutrophilia were all significantly associated with worse OS and PFS (Table 1) . Notably, raised ANC remained independently associated with increased risks of death (HR = 3.38; 95% CI 2.62-4.36; P < 0.0001, Table 1 ) and progression (HR = 2.52; 95% CI 1.97-3.21; P < 0.0001, Table 1 ).
baseline dNLR and survival
The ROC curve was used to determine specificity and sensitivity of different dNLR thresholds for survival (supplementary Figure S2 , available at Annals of Oncology online). The AUC was 0.65 (95% CI 0.60-0.69). The optimal cutoff of dNLR, as determined by AUC and Harrell's C values, was 3 (supplementary Table S2 , available at Annals of Oncology online).
One hundred and sixty-two patients (22.5%) presented with dNLR ≥ 3. The dNLR was associated with ECOG PS (P < 0.0001), but not with other variables (supplementary Table S1 , available at Annals of Oncology online).
Median OS and PFS were 9.2 (95% CI 8.2-10.4) and 4.3 (95% CI 3.8-5.2) months, respectively, for patients with dNLR < 3, and 2.7 (95% CI 2.3-3.4) months and 2.4 (95% CI 2.1-2.8) months, respectively, for patients with higher dNLR ( Figure 1C and D, P < 0.0001 for both). In multivariate analysis, ECOG PS > 0, the presence of brain and liver metastasis and raised dNLR were all significantly associated with worse OS and PFS ( Table 2 ). As presented in Table 2 , baseline dNLR ≥ 3 remained independently associated with double-increased risks of death (HR = 2.29; 95% CI 1.86-2.82; P < 0.0001) and progression (HR = 2.03; 95% CI 1.66-2.47; P < 0.0001).
baseline ANC and dNLR and survival
Baseline ANC and dNLR were used to group patients and to evaluate the prognostic relevance of the two factors combined. Group a included 533 patients with ANC < 7500 and dNLR < 3; group b included 121 patients with either ANC ≥ 7500 or Median values for OS were 9.4, 5.0 and 1.55 months for patients in group a, b and c, respectively (P for trend is <0.0001, Figure 1E ), and their respective survival rates were 43%, 23% and 2% at 12 months and 24%, 7% and 0% at 24 months. Independently of age, gender, ECOG PS, brain and/or liver metastasis, patients with high ANC and dNLR (group c) had an increased risk of death (HR = 5.76; 95% CI 4.29-7.75; P < 0.0001, Table 3 ) when compared with patients with ANC < 7500 and dNLR < 3 (group a). Median PFS were 4.4, 3.2 and 1.4 months, respectively, for patients of group a, b and c (P for trend is <0.0001, Figure 1F ). Multivariate analysis confirmed that patients in group c had an increased risk of progression (HR = 4.10; 95% CI 3.08-5.46; P < 0.0001, Table 3 ) when compared with patients in group a. Patients in group b (ANC ≥ 7500 or dNLR ≥ 3) showed an intermediate risk for both death and disease progression (Table 3) , with no significant differences as per ANC ≥ 7500 or dNLR ≥ 3 (supplementary Figure S3 , available at Annals of Oncology online). Elevated LDH is a poor prognostic factor for metastatic melanoma patients [17] . For 460 patients accrued in eight centers, LDH levels and the range of normality were available (supplementary Figure S1 , available at Annals of Oncology online). Baseline characteristics of these patients were comparable with those of the whole study population (supplementary Tables S1  and S3 , available at Annals of Oncology online). As only two patients had ECOG PS 2, they were grouped with those with ECOG PS of 1 for further analyses. In multivariate analyses that included age, gender, ECOG PS, LDH, brain and liver metastasis, ANC (supplementary Table S4 , available at Annals of Oncology online) and dNLR (supplementary Table S5 , available at Annals of Oncology online) emerged as the strongest prognostic variables for OS (HR = 3.81; 95% CI 2.73-5.32 for ANC and HR = 2.46; 95% CI 1.88-3.23 for dNLR). Similar results were obtained when patients with ECOG PS of 2 were excluded from the analyses (HR = 3.97; 95% CI 2.87-5.48 for ANC and HR = 2.42; 95% CI 1.86-3.16 for dNLR).
ANC, dNLR and LDH levels were used to stratify patients according to the presence of none (group A, N = 183), one (group B, N = 184), two (group C, N = 60) or three (group D, N = 33) elevated parameter, and OS was evaluated (Figure 2 ; P for trend is <0.0001). Multivariate analysis confirmed that an elevation of each variable was associated with a significantly increased risk of death (Table 4) . Notably, patients with high baseline ANC, dNLR and LDH (group D) had a 13-fold increased risk of death when compared with patients with ANC < 7500, dNLR < 3 and normal LDH (group A).
discussion
In the last years, the therapeutic opportunities for metastatic melanoma patients have radically changed thanks to newly available immunomodulatory antibodies and mutation-driven targeted therapies. The first in class, ipilimumab, was shown to improve the OS of metastatic melanoma patients [1, 2] , with a survival benefit that could last years after drug discontinuation [18, 19] . However, slow kinetic of ipilimumab-induced responses, low response rates, frequency of drug-related toxicities and the availability of new therapeutic options demand for objective markers to identify patients best suited to receive this therapy before therapy initiation.
Inflammation has been recognized as an enabling characteristic for cancer development and progression [20, 21] . As markers of systemic inflammation, raised ANC, NLR and dNLR have been addressed as independent predictors of survival in cancer patients original articles Annals of Oncology [13, 22, 23] . In melanoma patients undergoing immunotherapies, associations of elevated baseline ANC [9, 24] or NLR [10] [11] [12] with poor OS have been documented. In this study, we applied these markers to a large cohort of melanoma patients who received ipilimumab, and we confirmed that both baseline neutrophilia and elevated dNLR are independently and significantly associated with an increased risk of death and disease progression. Moreover, simultaneous elevation of both ANC and dNLR was associated with a 5.7-fold increased risk of death and a 4-fold increased risk of progression (Table 3) . Thus, using this criterion, it seemed possible to identify a subpopulation of patients who did not achieve a survival benefit from treatment. On the other hand, 43% and 23% of patients with both ANC < 7500 and dNLR < 3 were alive after 1 and 2 years, respectively, from therapy initiation. Therefore, although the absence of neutrophilia and dNLR < 3 are not sufficient to warrant for ipilimumab efficacy, they are associated with a greater PFS and OS. To our knowledge, this is the first observation of such a value of ANC and dNLR combined for metastatic melanoma patients receiving an immune-modulating therapy. The characterization of the biological mechanism underlying these findings might help to fully understand and exploit the value of these parameters.
In accordance with previous studies [3] [4] [5] [6] 8] , also here, elevated LDH was associated with poor OS (supplementary Tables  S4 and S5 , available at Annals of Oncology online). Furthermore, patients with raised ANC, dNLR and LDH showed 13-fold increased risk of death when compared with patients who had none of these markers elevated (Table 4) .
This study has some limitations. First, the identified cutoffs for ANC and dNLR need to be validated in external populations, and the best thresholds for ANC and dNLR combined have to be validated in a model combining the two factors. Second, the EAP lacked a control population not receiving ipilimumab, meaning that the study design did not allow to establish if ANC, dNLR and their combination are general prognostic markers, or predictive markers for response to ipilimumab. Given that elevated ANC and dNLR have been associated with a poor outcome in a variety of cancers under different treatment modalities [22, 23] , it seems plausible that also here, their global prognostic relevance is exceeding the predictive value. Prospective randomized studies aimed at dissecting the significance of these indexes specifically for patients in therapy with ipilimumab are needed. Nevertheless, the potential clinical utility of these markers for daily oncology practice stands.
Another limitation is the lack of M-stage information. Among stage IV patients, those with nonpulmonary visceral metastasis and/or elevated LDH have the worst prognosis [17] . Here, we showed that patients with liver and/or brain metastasis are indeed at higher risk of progression and death. However, high ANC and dNLR remained significantly associated with poor survival in multivariate analyses that included brain and/ or liver metastasis and LDH (supplementary Tables S4 and S5 , available at Annals of Oncology online).
Another limitation of this study is the lack of information on patient concurrent conditions and medications [12] . Co-morbidities (such as infections or inflammation) and the use of steroids may cause alterations in peripheral blood cell counts. In this study, the potential confounding effect of these parameters could not be assessed.
In conclusion, the landscape of therapies for metastatic melanoma patients is rapidly changing. The identification of patients who are more likely or unlikely to benefit from a therapy in advance of its initiation would allow to optimize disease-management strategies, by giving patients the treatment they are best suited to receive, sparing them from unnecessary drug-related toxicities and improving their quality of life.
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